DCC-2036, known as the lead "switch-control" inhibitor, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I. DCC-2036 inhibits BCR-ABL1 (T315I)-expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph (+) leukemia.
|Cell lines||Ba/F3 cells or primary Ph+ leukemia cells|
|Preparation method||Cell Proliferation Assays
Ba/F3 cells (3×103 cells/well) or primary Ph+ leukemia cells (5×104 cells/well) were plated in triplicate in 96-well plates containing test compounds. After 72h, viable cells were quantified by resazurin (O’Brien et al., 2000) or MTT (Roumiantsev et al., 2002) assay as described. Results represent an average of at least three independent experiments.
|Incubation time||72 h|
|Animal models||Allograft and retroviral BM transduction/transplantation mouse models of BCR-ABL1-induced leukemia|
|Formulation||0.5% CMC/1% Tween-80|
|Dosages||100 mg/kg once daily|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||PLoS One (2013). Figure 1. DCC-2036|
|Cell Lines||EOL-1 cells|
|Incubation Time||24 h|
|Results||DCC-2036 effectively decreased the phosphorylated-PDGFRa in BaF3 cells expressing FIP1L1-PDGFRa T674I mutant in a concentration- and time-dependent manner while the total protein level of PDGFRa was not affected.|
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare et al. Blood. 2011 Nov 10;118(19):5250-4. PMID: 21908430.
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Eide et al. Cancer Res. 2011 May 1;71(9):3189-95. PMID: 21505103.
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan et al. Cancer Cell. 2011 Apr 12;19(4):556-68. PMID: 21481795.
|Related Src-bcr-Abl Products|
AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice.
GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
Radotinib is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia.
Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
Dasatinib(BMS-354825) hydrochloride is a potent and dual Abl/ Src inhibitor IC50 of ＜1 nM/0.8 nM respectively; also inhibit c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.